High-Throughput Discovery With BIOPTIC's Andrey Dobry

Andrey Doronichev, known to many simply as Dobry, is perhaps best known for taking KZbin mobile. You heard that right. If it weren't for him and the teams he led, KZbin might still be a desktop experience. He went on to lead product strategy at Google before launching the startup Optic in 2022. What's that got to do with biotech, you ask? Well, it's Optic where he feels his greatest contributions are to come, and his sights are set squarely on disrupting the way we discover therapeutic targets. On this episode of the Business of Biotech, Dobry, Life Science Leader Chief Editor Ben Comer, and I explore the intersection of AI and biotech, discuss BIOPTIC's beginnings and its approach to leveraging advanced screening technologies for drug discovery, and address BIOPTIC's biggest challenges -- data access and industry skepticism.
Access this and hundreds of episodes of the Business of Biotech videocast under the Listen & Watch tab at bioprocessonline.com.
Get in touch with guest and topic suggestions: [e-mail]
Find Matt Pillar on LinkedIn: / matthewpillar
---
#businessofbiotech #biopharma #biotech
Subscribe to the podcast:
Apple - podcasts.apple...
Spotify - open.spotify.c...
KZbin - • The Business Of Biotec...